Monoclonal Antibody Therapy is AVAILABLE
and administered in my office
HERE IS A LOCATOR FOR MONOCLONAL ANTIBODIES
INFUSIONS IN YOUR AREA:
SHOULD YOU RECEIVE MONOCLONAL ANTIBODIES?
FIND OUT MORE >>>>>>>>>>>>>>>>>>
The latest monclonal antibodies are from AstraZeneca known as EVUSHELD
The only antibody therapy authorized in US for PRE-exposure prophylaxis
WHAT ARE THESE MONOCLONAL ANTI-BODIES ?
The Monoclonal Antibodies are investigational medicines used in adults and adolescents (12 years of age and older who weigh at least 88 pounds (40 kg)) who are at high risk for severe COVID‑19, including hospitalization or death for:
treatment of mild to moderate symptoms of COVID-19 within 10 days of symptoms onset.
post-exposure prophylaxis of COVID-19 in persons who are:
not fully vaccinated against COVID-19 (Individuals are considered to be fully vaccinated 2 weeks after their second vaccine dose in a 2-dose series [such as the Pfizer or Moderna vaccines], or 2 weeks after a single-dose vaccine [such as Johnson & Johnson’s Janssen vaccine]), or,
are not expected to build up enough of an immune response to the complete COVID-19 vaccination (for example, someone with immunocompromising conditions, including someone who is taking immunosuppressive medications), and
someone who is at high risk of being exposed to someone who is infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons)
have been exposed to someone who is infected with SARS-CoV-2. Close contact with someone who is infected with SARS-CoV-2 is defined as being within 6 feet for a total of 15 minutes or more, providing care at home to someone who is sick, having direct physical contact with the person (hugging or kissing, for example), sharing eating or drinking utensils, or being exposed to respiratory droplets from an infected person (sneezing or coughing, for example).
These Monoclonal Antibodies are investigational because it is still being studied. There is limited information known about the safety and effectiveness of using either of these therapies to treat people with COVID‑19 or to prevent COVID-19 in people who are at high risk of being exposed to someone who is infected with SARS-CoV-2.
REGEN-COV, Sotrovimab & Lilly's therapies are not authorized for pre-exposure prophylaxis for prevention of COVID-19 &
NOT A SUBSTITUTE FOR COVID-19 VACCINATION.
The FDA has authorized the emergency use of these Monoclonal Antibodies for the treatment of COVID‑19 and the post-exposure prevention of COVID-19 under an Emergency Use Authorization (EUA).
MONOCLONAL TREATMENT IS NOW AVAILABLE IN MY OFFICE
The information on this page can help you decide if you or a loved one may qualify for monoclonal antibody (mAb) treatment and, if you do qualify, how you can get mAb treatment.
People aged 12 or older may be considered at high risk for developing more serious symptoms—making them eligible for mAb treatment—depending on their health history and how long they’ve had symptoms of COVID-19.
PLEASE NOTE: WE DO NOT TREAT PATIENTS UNDER THE AGE OF 18
MONO-CLONAL ANTIBODIES THERAPY IS ADMINISTERED ONE OF TWO METHODS:
1- Intravenous Administration; The medication is administered by IV directly into your bloodstream
2- By simultaneous injection into the four quadrants of your abdomen
INSURANCE COVERAGE IS ALLOWED, CLICK HERE FOR MORE INFORMATION >>>
Dr. Aquino does NOT accept insurance, if you treat at his office, you must pay for the IV administration at the allowed fee of $450, The office will issue an invoice to you for your health insurance carrier and you may be reimbursed for all or part of it.
You can download or read the Regen-Cov patient guide here >>>
You can download or read the Lilly patient guide here >>>>>>>>
You can download or read the Sotrovimab patient guide here >>>